[1]

Represents warrants for ordinary shares issuable upon an exercise price of $52.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2024.

[2]

Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.

[3]

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in July 2020. As of March 31, 2025, 288,634 warrants were exercised for a total consideration of $3,556,976. During the three months that ended March 31, 2025, no warrants were exercised.

[4]

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of December 31, 2024, 32,880 warrants were exercised for total consideration of $359,625. During the twelve months that ended December 31, 2024, no warrants were exercised.

[5]

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.

[6]

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in December 2020. As of March 31, 2025, 514,010 warrants were exercised for a total consideration of $4,821,416. During the three months that ended March 31, 2025, no warrants were exercised.

[7]

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of December 31, 2024, 32,283 warrants were exercised for total consideration of $405,003. During the twelve months that ended December 31, 2024, no warrants were exercised.

[8]

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in February 2021.

[9]

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.

[10]

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in September 2021.

[11]

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.

[12]

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in January 2025.